Skip to main content
SpringerLink
Log in

Acne inversa/Hidradenitis suppurativa: Ein Update

Acne inversa/hidradenitis suppurativa: An update

  • Übersichten
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Acne inversa (AI)/Hidradenitis suppurativa ist eine chronisch rezidivierende, immunvermittelte Dermatose mit dem Charakter einer Systemerkrankung, die durch tief sitzende entzündliche Knoten, Abszesse, Fisteln und unterminierte Narben in Hautarealen mit apokrinen Drüsen gekennzeichnet ist. Neben den Hautveränderungen zeigen zahlreiche AI-Patienten metabolische Veränderungen, Spondylarthritis und Depressionen. AI führt zu einer massiven Einschränkung der Lebensqualität und des Sexuallebens der Betroffenen und mündet oft in sozialem Rückzug, Stigmatisierung, Arbeitsplatzverlust und Suizidgedanken. In diesem Übersichtsbeitrag haben wir die wichtigsten Fakten zu AI zusammengefasst und schlagen einen einfachen Algorithmus für die Behandlung dieser Erkrankung vor.

Abstract

Acne inversa (AI)/hidradenitis suppurativa is a chronic, recurrent, immune-mediated dermatosis characterized by deep inflammatory nodules, abscesses, fistulas, and undermined scars in skin areas bearing apocrine glands. In addition to the cutaneous manifestation, numerous AI patients show metabolic changes, spondyloarthritis, and depression. AI leads to a strong reduction in the quality of life and an impairment of the sexual life of affected individuals and often culminates in social withdrawal, stigmatization, unemployment, and suicidal thoughts. In this overview, we summarized the most important facts about AI and propose a simple algorithm for therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Zouboulis CC, Del Marmol V, Mrowietz U et al (2015) Hidradenitis suppurativa/acne Inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology 231:184–190

    Article  PubMed  Google Scholar 

  2. Saunte DM, Boer J, Stratigos A et al (2015) Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol 173:1546–1549

    Article  CAS  PubMed  Google Scholar 

  3. Jemec GB, Kimball AB (2015) Hidradenitis suppurativa: epidemiology and scope of the problem. J Am Acad Dermatol 73:S4–S7

    Article  PubMed  Google Scholar 

  4. Sabat R (2017) Acne inversa/Hidradenitis suppurativa: a challenge for the future. Hautarzt 68. https://doi.org/10.1007/s00105-017-4079-0

    Google Scholar 

  5. Sabat R, Chanwangpong A, Schneider-Burrus S et al (2012) Increased prevalence of metabolic syndrome in patients with acne inversa. PLOS ONE 7:e31810

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Egeberg A, Gislason GH, Hansen PR (2016) Risk of major adverse cardiovascular events and all-cause mortality in patients with Hidradenitis Suppurativa. JAMA Dermatol 152:429–434

    Article  PubMed  Google Scholar 

  7. Schneider-Burrus S, Witte-Haendel E, Christou D et al (2016) High prevalence of back pain and axial spondyloarthropathy in patients with hidradenitis suppurativa. Dermatology 232:606–612

    Article  PubMed  Google Scholar 

  8. Kurek A, Peters JEM, Sabat R, Sterry W, Schneider-Burrus S (2013) Depression is a frequent co-morbidity in patients with acne inversa. J Dtsch Dermatol Ges 11:743–749, 743–750

    PubMed  Google Scholar 

  9. Shavit E, Dreiher J, Freud T et al (2015) Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 29:371–376

    Article  CAS  PubMed  Google Scholar 

  10. Capuron L, Miller AH (2011) Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 130:226–238

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9:46–56

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Gelfand JM, Kimball AB, Mostow EN et al (2008) Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. Value Health 11:400–407

    Article  PubMed  Google Scholar 

  13. Tyring S, Gottlieb A, Papp K et al (2006) Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367:29–35

    Article  CAS  PubMed  Google Scholar 

  14. Deckers IE, Benhadou F, Koldijk MJ et al (2017) Inflammatory bowel disease is associated with hidradenitis suppurativa: results from a multicenter cross-sectional study. J Am Acad Dermatol 76:49–53

    Article  PubMed  Google Scholar 

  15. Matusiak L, Bieniek A, Szepietowski JC (2010) Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol 90:264–268

    Article  PubMed  Google Scholar 

  16. Wolkenstein P, Loundou A, Barrau K et al (2007) Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 56:621–623

    Article  PubMed  Google Scholar 

  17. Kurek A, Peters EM, Chanwangpong A et al (2012) Profound disturbances of sexual health in patients with acne inversa. J Am Acad Dermatol 67:422–428, 428 e421

    Article  PubMed  Google Scholar 

  18. Dufour DN, Emtestam L, Jemec GB (2014) Hidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease. Postgrad Med J 90:216–221 (quiz 220)

    Article  PubMed  PubMed Central  Google Scholar 

  19. Yasar NF, Uylas MU, Baspinar M et al (2016) Evaluating the use of hematological parameters in staging hidradenitis suppurativa. Wounds 28:87–91

    PubMed  Google Scholar 

  20. Makris GM, Poulakaki N, Papanota AM et al (2017) Vulvar, perianal and perineal cancer after hidradenitis suppurativa: a systematic review and pooled analysis. Dermatol Surg 43:107–115

    Article  CAS  PubMed  Google Scholar 

  21. Lapins J, Ye W, Nyren O, Emtestam L (2001) Incidence of cancer among patients with hidradenitis suppurativa. Arch Dermatol 137:730–734

    CAS  PubMed  Google Scholar 

  22. Jourabchi N, Fischer AH, Cimino-Mathews A, Waters KM, Okoye GA (2017) Squamous cell carcinoma complicating a chronic lesion of hidradenitis suppurativa: a case report and review of the literature. Int Wound J 14:435–438

    Article  PubMed  Google Scholar 

  23. Yu N, Long X, Lujan-Hernandez JR et al (2013) Marjolin’s ulcer: a preventable malignancy arising from scars. World J Surg Oncol 11:313

    Article  PubMed  PubMed Central  Google Scholar 

  24. Williams ST, Busby RC, DeMuth RJ, Nelson H (1991) Perineal hidradenitis suppurativa: presentation of two unusual complications and a review. Ann Plast Surg 26:456–462

    Article  CAS  PubMed  Google Scholar 

  25. Kimball AB, Okun MM, Williams DA et al (2016) Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med 375:422–434

    Article  CAS  PubMed  Google Scholar 

  26. Cosmatos I, Matcho A, Weinstein R, Montgomery MO, Stang P (2013) Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol 69:819

    Article  PubMed  Google Scholar 

  27. Vazquez BG, Alikhan A, Weaver AL, Wetter DA, Davis MD (2013) Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol 133:97–103

    Article  CAS  PubMed  Google Scholar 

  28. Revuz JE, Canoui-Poitrine F, Wolkenstein P et al (2008) Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 59:596–601

    Article  PubMed  Google Scholar 

  29. Jemec GB, Heidenheim M, Nielsen NH (1996) The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 35:191–194

    Article  CAS  PubMed  Google Scholar 

  30. Jemec GB (1988) The symptomatology of hidradenitis suppurativa in women. Br J Dermatol 119:345–350

    Article  CAS  PubMed  Google Scholar 

  31. von Laffert M, Stadie V, Wohlrab J, Marsch WC (2011) Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol 164:367–371

    Article  Google Scholar 

  32. Wolk K, Warszawska K, Hoeflich C et al (2011) Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol 186:1228–1239

    Article  CAS  PubMed  Google Scholar 

  33. Asadullah K, Sabat R, Wiese A et al (1999) Interleukin-10 in cutaneous disorders: implications for its pathophysiological importance and therapeutic use. Arch Dermatol Res 291:628–636

    Article  CAS  PubMed  Google Scholar 

  34. Wolk K, Witte E, Warszawska K et al (2009) The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol 39:3570–3581

    Article  CAS  PubMed  Google Scholar 

  35. Sabat R, Ouyang W, Wolk K (2014) Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov 13:21–38

    Article  CAS  PubMed  Google Scholar 

  36. Matusiak L, Bieniek A, Szepietowski JC (2014) Bacteriology of hidradenitis suppurativa—which antibiotics are the treatment of choice? Acta Derm Venereol 94:699–702

    Article  PubMed  Google Scholar 

  37. Ring HC, Thorsen J, Saunte DM et al (2017) The follicular skin microbiome in patients with hidradenitis suppurativa and healthy controls. JAMA Dermatol 153:897–905

    Article  PubMed  Google Scholar 

  38. Kelly G, Hughes R, McGarry T et al (2015) Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa. Br J Dermatol 173:1431–1439

    Article  CAS  PubMed  Google Scholar 

  39. Lima AL, Karl I, Giner T et al (2016) Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa. Br J Dermatol 174:514–521

    Article  CAS  PubMed  Google Scholar 

  40. Wolk K, Wenzel J, Tsaousi A et al (2017) Lipocalin-2 is expressed by activated granulocytes and keratinocytes in affected skin and reflects disease activity in acne inversa/hidradenitis suppurativa. Br J Dermatol. https://doi.org/10.1111/bjd.15424

    PubMed  Google Scholar 

  41. Chiricozzi A, Raimondo A, Lembo S et al (2016) Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. Expert Rev Clin Immunol 12:1299–1308

    Article  CAS  PubMed  Google Scholar 

  42. Karbach S, Croxford AL, Oelze M et al (2014) Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease. Arterioscler Thromb Vasc Biol 34:2658–2668

    Article  CAS  PubMed  Google Scholar 

  43. Wolk K, Sabat R (2016) Adipokines in psoriasis: an important link between skin inflammation and metabolic alterations. Rev Endocr Metab Disord 17:305–317

    Article  CAS  PubMed  Google Scholar 

  44. Sabat R, Wolk K (2015) Deciphering the role of interleukin-22 in metabolic alterations. Cell Biosci 15(5):68

    Article  Google Scholar 

  45. Sabat R, Schon MP, Schakel K (2016) Psoriasis. Hautarzt 67:420–421

    Article  CAS  PubMed  Google Scholar 

  46. Kirschke J, Hessam S, Bechara FG (2015) Hidradenitis suppurativa/acne inversa: an update. Hautarzt 66:413–422

    Article  CAS  PubMed  Google Scholar 

  47. Sartorius K, Lapins J, Emtestam L, Jemec GB (2003) Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol 149:211–213

    Article  CAS  PubMed  Google Scholar 

  48. Kimball AB, Jemec GB, Yang M et al (2014) Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol 171:1434–1442

    Article  CAS  PubMed  Google Scholar 

  49. Zouboulis CC, Tzellos T, Kyrgidis A et al (2017) Development and validation of IHS4, a novel dynamic scoring system to assess hidradenitis suppurativa/acne inversa severity. Br J Dermatol. https://doi.org/10.1111/bjd.15748

    Google Scholar 

  50. Matusiak L, Bieniek A, Szepietowski JC (2009) Soluble interleukin-2 receptor serum level is a useful marker of hidradenitis suppurativa clinical staging. Biomarkers 14:432–437

    Article  CAS  PubMed  Google Scholar 

  51. Matusiak L, Salomon J, Nowicka-Suszko D, Bieniek A, Szepietowski JC (2015) Chitinase-3-like protein 1 (YKL-40): novel Biomarker of Hidradenitis Suppurativa disease activity? Acta Derm Venereol 95:736–737

    Article  CAS  PubMed  Google Scholar 

  52. Tsaousi A, Witte E, Witte K et al (2016) MMP8 is increased in lesions and blood of acne inversa patients: a potential link to skin destruction and metabolic alterations. Mediat Inflamm 2016:4097574

    Article  Google Scholar 

  53. Gener G, Canoui-Poitrine F, Revuz JE et al (2009) Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology 219:148–154

    Article  CAS  PubMed  Google Scholar 

  54. Mendonca CO, Griffiths CE (2006) Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol 154:977–978

    Article  CAS  PubMed  Google Scholar 

  55. van der Zee HH, Boer J, Prens EP, Jemec GB (2009) The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology 219:143–147

    Article  PubMed  Google Scholar 

  56. Kimball AB, Kerdel F, Adams D et al (2012) Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med 157:846–855

    Article  PubMed  Google Scholar 

  57. Philipp S, Kokolakis G, Sabat R (2016) Systemic treatments for psoriasis and psoriatic arthritis. Hautarzt 67:464–471

    Article  CAS  PubMed  Google Scholar 

Download references

Danksagung

Die Autoren möchte sich bei Dr. Ellen Witte-Händel für die Diskussionen und Hilfe bei der Erstellung dieser Veröffentlichung herzlich bedanken.

Author information

Authors and Affiliations

  1. Interdisziplinäre Gruppe Molekulare Immunpathologie, Dermatologie/Med. Immunologie, Charité – Universitätsmedizin Berlin, Berlin, Deutschland

    R. Sabat, A. Tsaousi, S. Schneider-Burrus, G. Kokolakis & K. Wolk

  2. Psoriasis Forschungs- und BehandlungsCentrum, Klinik für Dermatologie, Venerologie und Allergologie und Institut für Medizinische Immunologie, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland

    R. Sabat, A. Tsaousi, G. Kokolakis & K. Wolk

  3. Hautzentrum Friedrichshain, Berlin, Deutschland

    J. Rossbacher

  4. Haut- und Laserzentrum Freising, Freising, Deutschland

    H. Kurzen

  5. Hautarztpraxis, Bremen, Deutschland

    T. Fadai & U. Schwichtenberg

  6. Zentrum für Dermatochirurgie, Havelklinik, Berlin, Deutschland

    S. Schneider-Burrus

Authors
  1. R. Sabat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Tsaousi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Rossbacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Kurzen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Fadai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. U. Schwichtenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Schneider-Burrus
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G. Kokolakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. K. Wolk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Sabat.

Ethics declarations

Interessenkonflikt

R. Sabat erhielt Projektunterstützung, Reisekostenunterstützung oder Vergütung für Tätigkeiten im Rahmen klinischer Studien, Referenten- oder Beratertätigkeiten in alphabetischer Reihenfolge von folgenden Firmen: AbbVie Inc., AbbVie Deutschland GmbH & Co. KG, Bayer Schering Pharma AG, Biogen IDEC GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Celgene International II Sàrl, Charité Research Organisation GmbH, Dr.Willmar Schwabe GmbH & Co. KG, Flexopharm GmbH & Co. KG, Generon Corporation ltd., Novartis Pharma GmbH, Parexel International GmbH, Pfizer Deutschland GmbH. A. Tsaousi, H. Kurzen und T. Fadai geben an, dass kein Interessenkonflikt besteht. J. Rossbacher erhielt Reisekostenunterstützung oder Vergütung für Tätigkeiten im Rahmen klinischer Studien, Referenten- oder Beratertätigkeiten in alphabetischer Reihenfolge von folgenden Firmen: AbbVie Inc., AbbVie Deutschland GmbH & Co. KG, Celgene International II Sàrl, Global Clinical Operations Janssen-Cilag GmbH, Parexel International GmbH, Pfizer Pharma GmbH. U. Schwichtenberg erhielt Vergütung für Tätigkeiten im Rahmen klinischer Studien, Referenten- oder Beratertätigkeiten, oder als Aktionär von folgenden Firmen: AbbVie Deutschland GmbH, Almirall Hermal GmbH, Astellas Pharma GmbH, Beiersdorf Derma Medical GmbH, Celgene GmbH, Janssen Cilag GmbH, Johnson & Johnson GmbH, LEO Pharma GmbH, L´Oréal GmbH, MEDA Pharma GmbH, Merz Pharmaceuticals GmbH, MSD SHARP & DOHME GmbH, Novartis Pharma GmbH, Pfizer GmbH und Medical Project Design GmbH. S. Schneider-Burrus erhielt Reisekostenunterstützung oder Vergütung für Tätigkeiten im Rahmen klinischer Studien, Referenten- oder Beratertätigkeiten in alphabetischer Reihenfolge von folgenden Firmen: AbbVie Inc., AbbVie Deutschland GmbH & Co. KG, Novartis Pharma GmbH, Roche Germany GmbH. G. Kokolakis war als Referent oder Berater tätig oder erhielt Erstattung von Reisekosten von AbbVie Deutschland GmbH & Co. KG, Actelion Pharmaceuticals Ltd., Basilea Pharmaceutica Ltd., Biogen IDEC GmbH, Celgene GmbH, Janssen-Cilag GmbH, LEO Pharma GmbH, Lilly Deutschland GmbH, MSD Sharp & Dohme GmbH, Novartis Pharma GmbH, Parexel International GmbH, Pfizer Deutschland GmbH. K. Wolk erhielt Projektunterstützung, Reisekostenunterstützung oder Vergütung für Referenten- oder Beratertätigkeiten in alphabetischer Reihenfolge von folgenden Firmen: AbbVie Deutschland GmbH & Co. KG, Bayer Schering Pharma AG, Generon Corporation ltd., Novartis Pharma GmbH, Parexel International GmbH und UCB Pharma GmbH.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren. Alle Patienten, die über Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts zu identifizieren sind, haben hierzu ihre schriftliche Einwilligung gegeben.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sabat, R., Tsaousi, A., Rossbacher, J. et al. Acne inversa/Hidradenitis suppurativa: Ein Update. Hautarzt 68, 999–1006 (2017). https://doi.org/10.1007/s00105-017-4082-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-017-4082-5

Schlüsselwörter

Keywords

Search

Navigation